PYMX - 4/7/10 Call Re PMX-30063 Phase 1b Results
1. There was mention of no serious adverse events found in the Phase 1b study, although there was some degree of liver elevation and a numbness/tingling side effect. It sounded like the liver elevations were minimal and well below the 3x upper limit threshold that normally gives cause for concern. With respect to the numbness/tingling, it was indicated that the effect was seen out to 10 days post treatment in certain instances. Is that cause for any type of concern? That seems strange that there would still be a numbness/tingling sensation out to 10 days post treatment. Even though this doesn't appear to be a concern now, I wonder if this could be signs of a more worrisome side effect that might occur in a longer duration, or different type of, study. Any thoughts are appreciated here.
2. I have just a general question myself on the MOA for PMX-30063 for Biomaven or any others that closely follow this program. I understand that PMX-30063 is patterned after human defense proteins. How has PMX-30063 been designed to succeed where natural human defense proteins fail? Is it simply a matter of PMX-30063 being many fold more potent than natural human defense proteins or is there some major structural difference that leads PYMX to believe that PMX-30063 can succeed against bacterial infections where natural human defense proteins fail?
3. PYMX is in discussions with pharmaceutical companies with respect to the partnering of PMX-30063. PYMX hopes a decision on whether the drug will be partnered or whether PYMX will go it alone in Phase 3 will be reached by the end of this year.
4. I noted several questions from David Miller around the 44 minute mark of the presentation. David, since I know you read and post here: (1) Were your questions related to safety, among other things, adequately addressed? (2) Any comments on the numbness/tingling out to 10 days? (3) What are your thoughts with respect to PMX-30063 and with PYMX itself generally? Do you like the risk-reward of the stock here?
